Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs)

Author(s): Ozgur Karcioglu*, Sarper Yilmaz, Göksu Afacan, Eylem Ersan, Derya Abuşka, Sehmus Zengin, Bilgen Ozkaya, Mandana Hosseinzadeh and Selman Yeniocak

Volume 20, Issue 2, 2022

Published on: 14 September, 2021

Page: [114 - 124] Pages: 11

DOI: 10.2174/1871525719666210914112402

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Direct (New-generation) Oral Anticoagulants (DOACs) have emerged as effective agents which are used in place of vitamin-K antagonists in treatment and prophylaxis of Venous Thromboembolism (VTE), atrial fibrillation and other thrombotic diseases. Among them, the FIIa- direct thrombin inhibitor dabigatran and FXa inhibitors (rivaroxaban, apixaban, edoxaban) are the most broadly used. Anticoagulant dosing may differ under special considerations. The patients’ physiological reserves, organ functional status and failures should be taken into account in clinical decision-making processes. The advantages and drawbacks of each specific agent should be weighed with special regard to metabolism, pharmacokinetics and pharmacodynamics, along with the efficiency of the agents in different indications. This article aims to review the most recent literature to highlight the usage and efficacy of the agents in different clinical conditions.

Keywords: Direct oral anticoagulants, new oral anticoagulants, anticoagulation, venous thromboembolism, thrombosis, thromboembolic disease.

« Previous Next »
Graphical Abstract

[1]
Sarich, T.C.; Seltzer, J.H.; Berkowitz, S.D.; Costin’, J.; Curnutte, J.T.; Gibson, C.M.; Hoffman, M.; Kaminskas, E.; Krucoff, M.W.; Levy, J.H.; Mintz, P.D.; Reilly, P.A.; Sager, P.T.; Singer, D.E.; Stockbridge, N.; Weitz, J.I.; Kowey, P.R. Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am. Heart J., 2015, 169(6), 751-757.
[http://dx.doi.org/10.1016/j.ahj.2015.03.010] [PMID: 26027611]
[2]
López-López, J.A.; Sterne, J.A.C.; Thom, H.H.Z.; Higgins, J.P.T.; Hingorani, A.D.; Okoli, G.N.; Davies, P.A.; Bodalia, P.N.; Bryden, P.A.; Welton, N.J.; Hollingworth, W.; Caldwell, D.M.; Savović, J.; Dias, S.; Salisbury, C.; Eaton, D.; Stephens-Boal, A.; Sofat, R. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ, 2017, 359, j5058.
[http://dx.doi.org/10.1136/bmj.j5058] [PMID: 29183961]
[3]
Schulman, S.; Kearon, C.; Kakkar, A.K.; Mismetti, P.; Schellong, S.; Eriksson, H.; Baanstra, D.; Schnee, J.; Goldhaber, S.Z. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med., 2009, 361(24), 2342-2352.
[http://dx.doi.org/10.1056/NEJMoa0906598] [PMID: 19966341]
[4]
Büller, H.R.; Prins, M.H.; Lensin, A.W.; Decousus, H.; Jacobson, B.F.; Minar, E.; Chlumsky, J.; Verhamme, P.; Wells, P.; Agnelli, G.; Cohen, A.; Berkowitz, S.D.; Bounameaux, H.; Davidson, B.L.; Misselwitz, F.; Gallus, A.S.; Raskob, G.E.; Schellong, S.; Segers, A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med., 2012, 366(14), 1287-1297.
[http://dx.doi.org/10.1056/NEJMoa1113572] [PMID: 22449293]
[5]
Agnelli, G.; Buller, H.R.; Cohen, A.; Curto, M.; Gallus, A.S.; Johnson, M.; Masiukiewicz, U.; Pak, R.; Thompson, J.; Raskob, G.E.; Weitz, J.I. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med., 2013, 369(9), 799-808.
[http://dx.doi.org/10.1056/NEJMoa1302507] [PMID: 23808982]
[6]
Büller, H.R.; Décousus, H.; Grosso, M.A.; Mercuri, M.; Middeldorp, S.; Prins, M.H.; Raskob, G.E.; Schellong, S.M.; Schwocho, L.; Segers, A.; Shi, M.; Verhamme, P.; Wells, P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med., 2013, 369(15), 1406-1415.
[http://dx.doi.org/10.1056/NEJMoa1306638] [PMID: 23991658]
[7]
Hoffman, M.; Goldstein, J.N.; Levy, J.H. The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. Int. J. Emerg. Med., 2018, 11(1), 55.
[http://dx.doi.org/10.1186/s12245-018-0215-6] [PMID: 31179943]
[8]
Raskob, G.E.; van Es, N.; Verhamme, P.; Carrier, M.; Di Nisio, M.; Garcia, D.; Grosso, M.A.; Kakkar, A.K.; Kovacs, M.J.; Mercuri, M.F.; Meyer, G.; Segers, A.; Shi, M.; Wang, T.F.; Yeo, E.; Zhang, G.; Zwicker, J.I.; Weitz, J.I.; Büller, H.R. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med., 2018, 378(7), 615-624.
[http://dx.doi.org/10.1056/NEJMoa1711948] [PMID: 29231094]
[9]
Guyatt, G.H.; Akl, E.A.; Crowther, M. Executive summary: Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012, 141(2 Suppl), 7-47.
[10]
Harenberg, J.; Beyer-Westendorf, J.; Crowther, M.; Douxfils, J.; Elalamy, I.; Verhamme, P.; Bauersachs, R.; Hetjens, S.; Weiss, C. Working group members. Accuracy of a rapid diagnostic test for the presence of direct oral factor xa or thrombin inhibitors in urine-a multicenter trial. Thromb. Haemost., 2020, 120(1), 132-140.
[http://dx.doi.org/10.1055/s-0039-1700545] [PMID: 31705521]
[11]
January, C.T.; Wann, L.S.; Calkins, H.; Chen, L.Y.; Cigarroa, J.E.; Cleveland, J.C., Jr; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; Furie, K.L.; Heidenreich, P.A.; Murray, K.T.; Shea, J.B.; Tracy, C.M.; Yancy, C.W. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation, 2019, 140(2), e125-e151.
[http://dx.doi.org/10.1161/CIR.0000000000000665] [PMID: 30686041]
[12]
Fick, D.M.; Semla, T.P.; Beizer, J.; Brandt, N.; Dombrowski, R.; DuBeau, C.E.; Eisenberg, W.; Epplin, J.J.; Flanagan, N.; Giovannetti, E. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc., 2015, 63(11), 2227-2246.
[http://dx.doi.org/10.1111/jgs.13702] [PMID: 26446832]
[13]
Raschi, E.; Bianchin, M.; Ageno, W.; De Ponti, R.; De Ponti, F. Risk-benefit profile of direct-acting oral anticoagulants in established therapeutic indications: An overview of systematic reviews and observational studies. Drug Saf., 2016, 39(12), 1175-1187.
[http://dx.doi.org/10.1007/s40264-016-0464-3] [PMID: 27696300]
[14]
de Vries, TAC; Hemels, MEW; Pisters, R; Jansen, RWMM; de Groot, JR Contraindications to DOACs in atrial fibrillation. Ned Tijdschr Geneeskd, 2020, 164, D4906.
[PMID: 33201637]
[15]
Steinberg, B.A.; Ballew, N.G.; Greiner, M.A.; Lippmann, S.J.; Curtis, L.H.; O’Brien, E.C.; Patel, M.R.; Piccini, J.P. Ischemic and bleeding outcomes in patients with atrial fibrillation and contraindications to oral anticoagulation. JACC Clin. Electrophysiol., 2019, 5(12), 1384-1392.
[http://dx.doi.org/10.1016/j.jacep.2019.07.011] [PMID: 31857036]
[16]
Spirk, D.; Sebastian, T.; Banyai, M.; Beer, J.H.; Mazzolai, L.; Baldi, T.; Aujesky, D.; Hayoz, D.; Engelberger, R.P.; Kaeslin, T.; Korte, W.; Escher, R.; Husmann, M.; Mollet, A.; Szucs, T.D.; Kucher, N. Venous thromboembolism and renal impairment: Insights from the swiss venous thromboembolism registry (SWIVTER). Semin. Thromb. Hemost., 2019, 45(8), 851-858.
[http://dx.doi.org/10.1055/s-0039-1698770] [PMID: 31622993]
[17]
Dalal, J.J.; Dhall, A.; Bhave, A. Current perspective on use of noac in clinical practice in India. J. Assoc. Physicians India, 2016, 64(4), 56-65.
[PMID: 27734642]
[18]
Hull, R.D.; Lip, G.Y.H. Venous thromboembolism: Anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Available from: http://www.uptodate.comAccessed May 28, 2018
[19]
Tomaselli, G.F.; Mahaffey, K.W.; Cuker, A.; Dobesh, P.P.; Doherty, J.U.; Eikelboom, J.W.; Florido, R.; Hucker, W.; Mehran, R.; Messé, S.R.; Pollack, C.V., Jr; Rodriguez, F.; Sarode, R.; Siegal, D.; Wiggins, B.S. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the american college of cardiology task force on expert consensus decision pathways. J. Am. Coll. Cardiol., 2017, 70(24), 3042-3067.
[http://dx.doi.org/10.1016/j.jacc.2017.09.1085] [PMID: 29203195]
[20]
Lip, G. Chronic anticoagulation after acute coronary syndromes. UpToDate, Available from: http://www.uptodate.comAccessed October 23, 2018
[21]
Lip, G.; Hull, R.D. Rationale and indications for indefinite anticoagulation in patients with venous thromboembolism. UpToDate, Available from: http://www.uptodate.comAccessed March 9, 2018
[22]
Eikelboom, J.W.; Connolly, S.J.; Bosch, J.; Dagenais, G.R.; Hart, R.G.; Shestakovska, O.; Diaz, R.; Alings, M.; Lonn, E.M.; Anand, S.S.; Widimsky, P.; Hori, M.; Avezum, A.; Piegas, L.S.; Branch, K.R.H.; Probstfield, J.; Bhatt, D.L.; Zhu, J.; Liang, Y.; Maggioni, A.P.; Lopez-Jaramillo, P.; O’Donnell, M.; Kakkar, A.K.; Fox, K.A.A.; Parkhomenko, A.N.; Ertl, G.; Störk, S.; Keltai, M.; Ryden, L.; Pogosova, N.; Dans, A.L.; Lanas, F.; Commerford, P.J.; Torp-Pedersen, C.; Guzik, T.J.; Verhamme, P.B.; Vinereanu, D.; Kim, J.H.; Tonkin, A.M.; Lewis, B.S.; Felix, C.; Yusoff, K.; Steg, P.G.; Metsarinne, K.P.; Cook Bruns, N.; Misselwitz, F.; Chen, E.; Leong, D.; Yusuf, S. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med., 2017, 377(14), 1319-1330.
[http://dx.doi.org/10.1056/NEJMoa1709118] [PMID: 28844192]
[23]
Crowther, M.A.; Cuker, A. Reduced-intensity rivaroxaban for the prevention of recurrent venous thromboembolism. N. Engl. J. Med., 2017, 376(13), 1279-1280.
[http://dx.doi.org/10.1056/NEJMe1701628] [PMID: 28316277]
[24]
Berger, J.S. Oral antiplatelet therapy for secondary prevention of acute coronary syndrome. Am. J. Cardiovasc. Drugs, 2018, 18(6), 457-472.
[http://dx.doi.org/10.1007/s40256-018-0291-2] [PMID: 29987548]
[25]
Eikelboom, J.W.; Connolly, S.J.; Bosch, J.; Dagenais, G.R.; Hart, R.G.; Shestakovska, O.; Diaz, R.; Alings, M.; Lonn, E.M.; Anand, S.S.; Widimsky, P.; Hori, M.; Avezum, A.; Piegas, L.S.; Branch, K.R.H.; Probstfield, J.; Bhatt, D.L.; Zhu, J.; Liang, Y.; Maggioni, A.P.; Lopez-Jaramillo, P.; O’Donnell, M.; Kakkar, A.K.; Fox, K.A.A.; Parkhomenko, A.N.; Ertl, G.; Störk, S.; Keltai, M.; Ryden, L.; Pogosova, N.; Dans, A.L.; Lanas, F.; Commerford, P.J.; Torp-Pedersen, C.; Guzik, T.J.; Verhamme, P.B.; Vinereanu, D.; Kim, J.H.; Tonkin, A.M.; Lewis, B.S.; Felix, C.; Yusoff, K.; Steg, P.G.; Metsarinne, K.P.; Cook Bruns, N.; Misselwitz, F.; Chen, E.; Leong, D.; Yusuf, S. COMPASS investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med., 2017, 377(14), 1319-1330.
[http://dx.doi.org/10.1056/NEJMoa1709118] [PMID: 28844192]
[26]
Xarelto (rivaroxaban) [prescribing information]; Janssen Pharmaceuticals Inc: Titusville, NJ, 2019. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf
[27]
Stangier, J.; Stähle, H.; Rathgen, K.; Roth, W.; Shakeri-Nejad, K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J. Clin. Pharmacol., 2008, 48(12), 1411-1419.
[http://dx.doi.org/10.1177/0091270008324179] [PMID: 18827075]
[28]
Duffett, L; Castellucci, LA; Forgie, MA Pulmonary embolism: Update on management and controversies. BMJ, 2020, 370, m2177.
[http://dx.doi.org/10.1136/bmj.m2177]
[29]
Panahi, L.; Udeani, G.; Horseman, M.; Weston, J.; Samuel, N.; Joseph, M.; Mora, A.; Bazan, D. Review of medical therapies for the management of pulmonary embolism. Medicina (Kaunas), 2021, 57(2), 110.
[http://dx.doi.org/10.3390/medicina57020110] [PMID: 33530544]
[30]
Lopes, R.D.; Heizer, G.; Aronson, R.; Vora, A.N.; Massaro, T.; Mehran, R.; Goodman, S.G.; Windecker, S.; Darius, H.; Li, J.; Averkov, O.; Bahit, M.C.; Berwanger, O.; Budaj, A.; Hijazi, Z.; Parkhomenko, A.; Sinnaeve, P.; Storey, R.F.; Thiele, H.; Vinereanu, D.; Granger, C.B.; Alexander, J.H. AUGUSTUS investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N. Engl. J. Med., 2019, 380(16), 1509-1524.
[http://dx.doi.org/10.1056/NEJMoa1817083] [PMID: 30883055]
[31]
Byon, W.; Garonzik, S.; Boyd, R.A.; Frost, C.E. Apixaban: A clinical pharmacokinetic and pharmacodynamic review. Clin. Pharmacokinet., 2019, 58(10), 1265-1279.
[http://dx.doi.org/10.1007/s40262-019-00775-z] [PMID: 31089975]
[32]
Giugliano, R.P.; Ruff, C.T.; Rost, N.S.; Silverman, S.; Wiviott, S.D.; Lowe, C.; Deenadayalu, N.; Murphy, S.A.; Grip, L.T.; Betcher, J.M.; Duggal, A.; Dave, J.; Shi, M.; Mercuri, M.; Antman, E.M.; Braunwald, E. ENGAGE AF-TIMI 48 investigators. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48. Stroke, 2014, 45(8), 2372-2378.
[http://dx.doi.org/10.1161/STROKEAHA.114.006025] [PMID: 24947287]
[33]
Roberti, R.; Iannone, L.F.; Palleria, C.; Curcio, A.; Rossi, M.; Sciacqua, A.; Armentaro, G.; Vero, A.; Manti, A.; Cassano, V.; Russo, E.; De Sarro, G.; Citraro, R. Direct oral anticoagulants: From randomized clinical trials to real-world clinical practice. Front. Pharmacol., 2021, 12, 684638.
[http://dx.doi.org/10.3389/fphar.2021.684638] [PMID: 34122113]
[34]
Giugliano, R.P.; Ruff, C.T.; Braunwald, E.; Murphy, S.A.; Wiviott, S.D.; Halperin, J.L.; Waldo, A.L.; Ezekowitz, M.D.; Weitz, J.I.; Špinar, J.; Ruzyllo, W.; Ruda, M.; Koretsune, Y.; Betcher, J.; Shi, M.; Grip, L.T.; Patel, S.P.; Patel, I.; Hanyok, J.J.; Mercuri, M.; Antman, E.M. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2013, 369(22), 2093-2104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[35]
Rost, N.S.; Giugliano, R.P.; Ruff, C.T.; Murphy, S.A.; Crompton, A.E.; Norden, A.D.; Silverman, S.; Singhal, A.B.; Nicolau, J.C.; SomaRaju, B.; Mercuri, M.F.; Antman, E.M.; Braunwald, E. ENGAGE AF-TIMI 48 investigators. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: Findings from engage af-timi 48 (effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Stroke, 2016, 47(8), 2075-2082.
[http://dx.doi.org/10.1161/STROKEAHA.116.013540] [PMID: 27387994]
[36]
Giugliano, R.P.; Ruff, C.T.; Wiviott, S.D.; Nordio, F.; Murphy, S.A.; Kappelhof, J.A.; Shi, M.; Mercuri, M.F.; Antman, E.M.; Braunwald, E. Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: Insights from the engage af-timi 48 trial. Am. J. Med., 2016, 129(8), 850-857.e2.
[http://dx.doi.org/10.1016/j.amjmed.2016.02.028] [PMID: 26994510]
[37]
Steffel, J.; Verhamme, P.; Potpara, T.S.; Albaladejo, P.; Antz, M.; Desteghe, L.; Haeusler, K.G.; Oldgren, J.; Reinecke, H.; Roldan-Schilling, V.; Rowell, N.; Sinnaeve, P.; Collins, R.; Camm, A.J.; Heidbüchel, H. ESC scientific document group. The 2018 european heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J., 2018, 39(16), 1330-1393.
[http://dx.doi.org/10.1093/eurheartj/ehy136] [PMID: 29562325]
[38]
Kuno, T.; Ueyama, H.; Takagi, H.; Ando, T.; Numasawa, Y.; Briasoulis, A.; Fox, J.; Bangalore, S. Meta-analysis of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am. J. Cardiol., 2020, 125(4), 521-527.
[http://dx.doi.org/10.1016/j.amjcard.2019.11.022] [PMID: 31839147]
[39]
Bose, G.; Graveline, J.; Yogendrakumar, V.; Shorr, R.; Fergusson, D.A.; Le Gal, G.; Coutinho, J.; Mendonça, M.; Viana-Baptista, M.; Nagel, S.; Dowlatshahi, D. Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review. BMJ Open, 2021, 11(2), e040212.
[http://dx.doi.org/10.1136/bmjopen-2020-040212] [PMID: 33593766]
[40]
Martin, K.; Beyer-Westendorf, J.; Davidson, B.L.; Huisman, M.V.; Sandset, P.M.; Moll, S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J. Thromb. Haemost., 2016, 14(6), 1308-1313.
[http://dx.doi.org/10.1111/jth.13323] [PMID: 27299806]
[41]
Lachant, D.J.; Bach, C.; Fe, A.; White, R.J.; Lachant, N.A. Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. ERJ Open Res., 2021, 7(1), 00554-02020.
[http://dx.doi.org/10.1183/23120541.00554-2020] [PMID: 33569503]
[42]
Deitelzweig, S.; Keshishian, A.; Kang, A.; Dhamane, A.D.; Luo, X.; Li, X.; Balachander, N.; Rosenblatt, L.; Mardekian, J.; Pan, X.; Fusco, M.D.; Garcia Reeves, A.B.; Yuce, H.; Lip, G.Y.H. Effectiveness and safety of oral anticoagulants among nvaf patients with obesity: Insights from the aristophanes study. J. Clin. Med., 2020, 9(6), 1633.
[http://dx.doi.org/10.3390/jcm9061633] [PMID: 32481607]
[43]
Heidbuchel, H.; Verhamme, P.; Alings, M.; Antz, M.; Diener, H.C.; Hacke, W.; Oldgren, J.; Sinnaeve, P.; Camm, A.J.; Kirchhof, P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17(10), 1467-1507.
[http://dx.doi.org/10.1093/europace/euv309] [PMID: 26324838]
[44]
Riess, H.; Ay, C.; Bauersachs, R.; Becattini, C.; Beyer-Westendorf, J.; Cajfinger, F.; Chau, I.; Cohen, A.T.; Khorana, A.A.; Maraveyas, A.; Renni, M.; Young, A.M. Use of direct oral anticoagulants in patients with cancer: Practical considerations for the management of patients with nausea or vomiting. Oncologist, 2018, 23(7), 822-839.
[http://dx.doi.org/10.1634/theoncologist.2017-0473] [PMID: 29650686]
[45]
Alhousani, M.; Malik, S.U.; Abu-Hashyeh, A.; Poznanski, N.J.; Al-Hasan, S.; Roth, D.F.; Alsharedi, M.; Mustafa, B. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis. Thromb. Res., 2021, 198, 103-114.
[http://dx.doi.org/10.1016/j.thromres.2020.11.036] [PMID: 33310644]
[46]
Kim, K.S.; Song, J.W.; Soh, S.; Kwak, Y.L.; Shim, J.K. Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations. Anesth. Pain Med., 2020, 15(2), 133-142.
[http://dx.doi.org/10.17085/apm.2020.15.2.133] [PMID: 33329805]
[47]
Eller, T.; Flieder, T.; Fox, V.; Gripp, T.; Dittrich, M.; Kuhn, J.; Alban, S.; Knabbe, C.; Birschmann, I. Direct oral anticoagulants and heparins: laboratory values and pitfalls in ‘bridging therapy’. Eur. J. Cardiothorac. Surg., 2017, 51(4), 624-632.
[http://dx.doi.org/10.1093/ejcts/ezw368] [PMID: 28043992]
[48]
Mainbourg, S.; Cucherat, M.; Provencher, S.; Bertoletti, L.; Nony, P.; Gueyffier, F.; Mismetti, P.; Grange, C.; Durieu, I.; Kilo, R.; Laporte, S.; Grenet, G.; Lega, J.C. META-EMBOL group. Twice- or once-daily dosing of direct oral anticoagulants, a systematic review and meta-analysis. Thromb. Res., 2021, 197, 24-32.
[http://dx.doi.org/10.1016/j.thromres.2020.10.011] [PMID: 33161284]
[49]
Ortel, T.L.; Neumann, I.; Ageno, W.; Beyth, R.; Clark, N.P.; Cuker, A.; Hutten, B.A.; Jaff, M.R.; Manja, V.; Schulman, S.; Thurston, C.; Vedantham, S.; Verhamme, P.; Witt, D.M.; D Florez, I.; Izcovich, A.; Nieuwlaat, R.; Ross, S.; J Schünemann, H.; Wiercioch, W.; Zhang, Y.; Zhang, Y. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv., 2020, 4(19), 4693-4738.
[http://dx.doi.org/10.1182/bloodadvances.2020001830] [PMID: 33007077]

Rights & Permissions Print Cite
Article Metrics
77
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy